Glucose transporters: Important regulators of endometrial cancer therapy sensitivity

Glucose is of great importance in cancer cellular metabolism. Working together with several glucose transporters (GLUTs), it provides enough energy for biological growth. The main glucose transporters in endometrial cancer (EC) are Class 1 (GLUTs 1-4) and Class 3 (GLUTs 6 and 8), and the overexpress...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 933827
Main Authors Zhang, Xing, Lu, Jia-Jing, Abudukeyoumu, Ayitila, Hou, Ding-Yu, Dong, Jing, Wu, Jiang-Nan, Liu, Li-Bing, Li, Ming-Qing, Xie, Feng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.08.2022
Subjects
angiogenesis
apoptosis
endometrial cancer
glucose transporter
Oncology
proliferation
therapy sensitivity
endometrial cancer
apoptosis
therapy sensitivity
glucose transporter
proliferation
angiogenesis
Online AccessGet full text

Cover

More Information
Summary:Glucose is of great importance in cancer cellular metabolism. Working together with several glucose transporters (GLUTs), it provides enough energy for biological growth. The main glucose transporters in endometrial cancer (EC) are Class 1 (GLUTs 1-4) and Class 3 (GLUTs 6 and 8), and the overexpression of these GLUTs has been observed. Apart from providing abundant glucose uptake, these highly expressed GLUTs also participate in the activation of many crucial signaling pathways concerning the proliferation, angiogenesis, and metastasis of EC. In addition, overexpressed GLUTs may also cause endometrial cancer cells (ECCs) to be insensitive to hormone therapy or even resistant to radiotherapy and chemoradiotherapy. Therefore, GLUT inhibitors may hopefully become a sensitizer for EC precision-targeted therapies. This review aims to summarize the expression regulation, function, and therapy sensitivity of GLUTs in ECCs, aiming to provide a new clue for better diagnosis and treatment of EC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Andrzej Semczuk, Medical University of Lublin, Poland
Reviewed by: Keith R. Laderoute, Consultant, Redwood City, CA, United States; Pengming Sun, Fujian Medical University, China
These authors share first authorship
This article was submitted to Gynecological Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.933827